Benign form of myasthenia gravis after nivolumab treatment

Muscle Nerve. 2016 Sep;54(3):507-9. doi: 10.1002/mus.25212. Epub 2016 Jul 9.

Authors

Giorgia Sciacca¹, Alessandra Nicoletti¹, Luigi Rampello¹, Laura Noto², Hector J Soto Parra², Mario Zappia¹

Affiliations

¹ Department "G. F. Ingrassia", Section of Neurosciences, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy.
² Oncology Unit, Policlinico Hospital, Catania, Italy.

PMID: 27287688
DOI: 10.1002/mus.25212

No abstract available

Publication types

Case Reports

MeSH terms

Adenocarcinoma / drug therapy
Aged, 80 and over
Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents / adverse effects*
Brain Neoplasms / drug therapy
Humans
Male
Myasthenia Gravis / chemically induced*
Myasthenia Gravis / pathology
Nivolumab

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Nivolumab